260 related articles for article (PubMed ID: 26435496)
1. First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review.
Lassen D; Ennis ZN; Damkier P
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):32-6. PubMed ID: 26435496
[TBL] [Abstract][Full Text] [Related]
2. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study.
Huybrechts KF; Bateman BT; Pawar A; Bessette LG; Mogun H; Levin R; Li H; Motsko S; Scantamburlo Fernandes MF; Upadhyaya HP; Hernandez-Diaz S
BMJ; 2020 Feb; 368():m237. PubMed ID: 32075794
[TBL] [Abstract][Full Text] [Related]
3. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review.
Bellantuono C; Vargas M; Mandarelli G; Nardi B; Martini MG
Hum Psychopharmacol; 2015 May; 30(3):143-51. PubMed ID: 25784291
[TBL] [Abstract][Full Text] [Related]
4. Severe Venlafaxine Withdrawal Successfully Treated With a Short Course of Duloxetine.
Cutler N
Prim Care Companion CNS Disord; 2017 Feb; 19(1):. PubMed ID: 28196312
[No Abstract] [Full Text] [Related]
5. Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis.
Renoux C; Lix LM; Patenaude V; Bresee LC; Paterson JM; Lafrance JP; Tamim H; Mahmud SM; Alsabbagh MW; Hemmelgarn B; Dormuth CR; Ernst P;
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1716-22. PubMed ID: 26231193
[TBL] [Abstract][Full Text] [Related]
6. Exposure to duloxetine during pregnancy and risk of congenital malformations and stillbirth: A nationwide cohort study in Denmark and Sweden.
Ankarfeldt MZ; Petersen J; Andersen JT; Li H; Motsko SP; Fast T; Hede SM; Jimenez-Solem E
PLoS Med; 2021 Nov; 18(11):e1003851. PubMed ID: 34807906
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy.
Farshchian N; Alavi A; Heydarheydari S; Moradian N
Cancer Chemother Pharmacol; 2018 Nov; 82(5):787-793. PubMed ID: 30105459
[TBL] [Abstract][Full Text] [Related]
8. Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay.
Islin J; Munkboel CH; Styrishave B
Toxicol In Vitro; 2018 Mar; 47():63-71. PubMed ID: 29100959
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of cardiac and neuronal Na(+) channels by the selective serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine.
Stoetzer C; Papenberg B; Doll T; Völker M; Heineke J; Stoetzer M; Wegner F; Leffler A
Eur J Pharmacol; 2016 Jul; 783():1-10. PubMed ID: 27130441
[TBL] [Abstract][Full Text] [Related]
10. In utero exposure to venlafaxine, a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat.
Laurent L; Huang C; Ernest SR; Berard A; Vaillancourt C; Hales BF
Birth Defects Res A Clin Mol Teratol; 2016 Dec; 106(12):1044-1055. PubMed ID: 27384265
[TBL] [Abstract][Full Text] [Related]
11. How Does Usage of Serotonin Noradrenaline Reuptake Inhibitors Affect Intraocular Pressure in Depression Patients?
Uçan Gündüz G; Parmak Yener N; Kılınçel O; Gündüz C
J Ocul Pharmacol Ther; 2018 May; 34(4):354-359. PubMed ID: 29446702
[TBL] [Abstract][Full Text] [Related]
12. Venlafaxine induced QTc interval prolongation in a therapeutic dose.
Bavle A
Asian J Psychiatr; 2015 Aug; 16():63-4. PubMed ID: 26187237
[TBL] [Abstract][Full Text] [Related]
13. Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects.
Anderson KN; Lind JN; Simeone RM; Bobo WV; Mitchell AA; Riehle-Colarusso T; Polen KN; Reefhuis J
JAMA Psychiatry; 2020 Dec; 77(12):1246-1255. PubMed ID: 32777011
[TBL] [Abstract][Full Text] [Related]
14. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database.
Lin ND; Norman H; Regev A; Perahia DG; Li H; Chang CL; Dore DD
BMC Gastroenterol; 2015 Oct; 15():134. PubMed ID: 26467777
[TBL] [Abstract][Full Text] [Related]
15. A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.
Yılmaz R; Üstün D; Tuncer Uzun S; Reisli R; Türk Ş
Agri; 2018 Oct; 30(4):199-201. PubMed ID: 30403275
[TBL] [Abstract][Full Text] [Related]
16. Apathy symptoms induced by low-dose venlafaxine: Two cases.
Sato S; Sodeyama N; Matsuzaki A; Shiratori Y
Neuropsychopharmacol Rep; 2020 Jun; 40(2):196-197. PubMed ID: 32267090
[TBL] [Abstract][Full Text] [Related]
17. [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain].
Rejas Gutiérrez J; Blanca Tamayo M; Gascón Barrachina J; Armada Peláez B
Rev Psiquiatr Salud Ment; 2016; 9(2):87-96. PubMed ID: 26475204
[TBL] [Abstract][Full Text] [Related]
18. Influence of Different Antidepressants on Ocular Surface in Patients With Major Depressive Disorder.
Işik-Ulusoy S; Ulusoy MO
J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):49-52. PubMed ID: 33347023
[TBL] [Abstract][Full Text] [Related]
19. Differences in the placebo response in duloxetine and venlafaxine trials.
Breilmann J; Furukawa TA; Becker T; Koesters M
Acta Psychiatr Scand; 2018 Jun; 137(6):472-480. PubMed ID: 29603140
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability.
Xu Y; Bai SJ; Lan XH; Qin B; Huang T; Xie P
Braz J Med Biol Res; 2016 May; 49(6):. PubMed ID: 27240293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
